MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
ROCKVILLE, Md., June 23, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protege, the Company's Phase 3 clinical study of teplizumab in type 1 diabetes patients, will be presented at the American Diabetes Association's 71st Scientific Sessions symposium in San Diego, California on June 28, 2011 at 9:10 a.m. PDT.
Dr. Nicole Sherry, Director of the Diabetes Center at Massachusetts General Hospital for Children, and a lead investigator in the Protege study, will be presenting the results of the Phase 3 data as well as the results of exploratory post-hoc analyses.
Teplizumab, also called MGA031 and hOKT3gamma1 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhance beneficial regulatory T cell functions, thus promoting immune tolerance. MacroGenics retains full worldwide rights to teplizumab.
About MacroGenics, Inc.
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a method for generating cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) technology, which allows the company to incorporate multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc. For more information about MacroGenics, please visit www.macrogenics.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.
SOURCE MacroGenics, Inc.
CONTACT: Scott Koenig, M.D., Ph.D., President and CEO, or Jim Karrels, Vice President, CFO, both of MacroGenics, Inc., +1-301-251-5172, email@example.com
Web Site: http://www.macrogenics.com
Posted: June 2011